Pay in 4 interest-free payments of $6.25 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
It increases H3K4 methylation selectively at genomic regions bound by LSD1
1]heptan-2-yl)prop-2-en-1-one
890190-22-4
or BxPC-3 pancreatic cancer
SCR7: a NHEJ inhibitor promotes the efficiency of HDR 4–5-fold for CRISPR editing in both human and mouse cell lines
Canertinib HCl - CAS# 289499-45-2 60273 It increases H3K4 methylation selectivelyCanertinib, also known as CI1033 and PD183805, CAS No. 289499 45 2, is a potent ErbB inhibitor for the treatment of cancer. It is an irreversible tyrosine kinase inhibitor with activity against EGFR (IC50 0. 8 nM), HER 2 (IC50 19 nM) and ErbB 4 (IC50 7 nM). By 2015, Pfizer had discontinued development of the drug. Canertinib has been reported as a substrate for OATP1B3. Interaction of canertinib with OATP1B3 may alter its hepatic disposition and can